- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04341077
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
April 8, 2020 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Phase 1, Open-Label, One-Center Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will be a single-center, open-label, single dosing Fluzoparib study in healthy Chinese subjects to evaluate the pharmacokinetics and safety
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yuya Wang, Ph.D
- Phone Number: +86-13918749176
- Email: wangyuya@hrglobe.cn
Study Contact Backup
- Name: Jie Sun
- Phone Number: +86-15921538635
- Email: sunjie@hrglobe.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy Chinese subjects, male and female, 18 to 45 years of age, inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests;
- Male body weight ≥50 kg, female body weight ≥45 kg, body mass index (BMI) between ≥18.0 and ≤29.0 kg/m2, inclusive;
Female subjects agree not to be pregnant or lactating from beginning of the study screening to 90 days after trial completion:
- A negative blood and urine pregnancy test for females of childbearing potential at Screening and at Check-in, respectively;
- Females of reproductive potential are willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy; A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year), when used consistently and correctly. Females of non-childbearing potential will not be required to use contraception. Females of non-child bearing potential are defined as permanently sterile (eg, due to hysterectomy) or postmenopausal (defined as at least 12 months following cessation of menses without an alternative medical cause and serum FSH levels >25 IU/L).
- Males agree to refrain from donating sperm and fathering a child during the study and for at least 90 days after fluzoparib administration; male participants must agree to remain abstinent or must ensure a condom is used for all sexual activity (with a male or female partner) for this same duration.
- Able and willing to refrain from caffeine or caffeine-containing products, alcohol, fruit juices, and smoking/tobacco products from at least 48 hours prior to Check-In until the end of Safety Follow Up;
- Able and willing to refrain from eating and drinking poppy seed-containing products and grapefruit-related citrus fruits (eg, Seville oranges, pomelos) within 7 days prior to dosing until after collection of the final PK blood sample (Day 4);
- Able and willing to refrain from strenuous exercise (heavy lifting, weight training, calisthenics, aerobics) within 7 days prior to dosing until after collection of the final PK blood sample (Day 4);
- Willing and able to comply with all scheduled visits, study procedures, and provides written informed consent.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neuropsychiatric disease, or any condition that may affect drug absorption, distribution, metabolism, and excretion;
- Had a severe infection, trauma or major surgery within 4 weeks of screening and at Check-In; plan to have a surgery during the trial;
- A past medical history of ECG abnormalities, documented cardiac arrhythmias, or cardiovascular disease; or QTcF interval >450 msec for males, >470 msec for females, or <300 msec;
- Subject's systolic blood pressure (SBP) is >140 or <90 mmHg, diastolic blood pressure (DBP) is >90 or <50 mmHg, resting heart rate <40 or >100 bpm, and respiratory rate <10 or >20 breaths/min at Screening or Check-in after resting in a semi-supine position for 5 minutes. Vitals can be repeated twice (a minimum of 1 to 2 minutes apart) based on the investigator's judgment;
- History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (eg, hepatitis B or C);
- Subject has a history of type 1 hypersensitivity to any medication;
- Subject has evidence of substance abuse, a history of substance abuse, or is positive for drugs of abuse (eg, methamphetamines, opiates, methadone, cocaine, amphetamines, cannabinoids, tricyclic antidepressants, phencyclidine, barbiturates, benzodiazepines), or alcohol at Screening and Check-in (Day -1);
- History of symptomatic hypoglycemia;
- Subjects who smoke more than 5 cigarettes per day or will not refrain from smoking starting from at least 48 hours prior to screening and check-in on Day -1, and during the study;
- History of regular alcohol consumption in the past 3 months exceeding an average weekly intake of 14 standard drinks; 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor;
- Subject has used prescription medications within 14 days or, as per PI discretion, over-the-counter medications, dietary/nutritional supplements (except hormonal contraceptives, paracetamol under 2 grams/day, vitamin supplements) within 7 days or 5 half-lives prior to fluzoparib administration;
- Treatment with any investigational drug within 3 months (or 5 half-lives, whichever is longer) of dosing;
- Use of medications affecting liver metabolism within 1 month of screening;
- Blood donation or loss of more than 200 mL of blood within 1 month of screening; or blood donation or loss of more than 400 mL of blood within 3 months of screening; or received blood within 8 weeks of screening;
- Any other major illness/condition that, in the investigator's judgment, substantially increased the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SHR3162
A single dose of fluzoparib was administered orally
|
A single oral dose of fluzoparib on Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: from Day1 to Day4
|
Time of the observed maximum plasma concentration of SHR3162
|
from Day1 to Day4
|
Cmax
Time Frame: from Day1 to Day4
|
Maximum observed plasma concentration of SHR3162
|
from Day1 to Day4
|
AUC0-t
Time Frame: from Day1 to Day4
|
Area under the plasma concentration-time curve from the time zero to the last quantifiable concentration of SHR3162
|
from Day1 to Day4
|
AUC0-inf
Time Frame: from Day1 to Day4
|
• Area under the plasma concentration-time curve from time zero extrapolated to infinity of SHR3162
|
from Day1 to Day4
|
T1/2
Time Frame: from Day1 to Day4
|
Terminal plasma elimination half-life of SHR3162
|
from Day1 to Day4
|
CL/F
Time Frame: from Day1 to Day4
|
Apparent clearance of SHR3162
|
from Day1 to Day4
|
Vz/F
Time Frame: from Day1 to Day4
|
Apparent volume of distribution of SHR3162
|
from Day1 to Day4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
April 10, 2020
Primary Completion (ANTICIPATED)
April 20, 2020
Study Completion (ANTICIPATED)
October 20, 2020
Study Registration Dates
First Submitted
April 8, 2020
First Submitted That Met QC Criteria
April 8, 2020
First Posted (ACTUAL)
April 10, 2020
Study Record Updates
Last Update Posted (ACTUAL)
April 10, 2020
Last Update Submitted That Met QC Criteria
April 8, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- SHR3162-I-114
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Adult Male and Female Volunteers
-
Intarcia TherapeuticsCompletedHealthy Adult Male and Female VolunteersNetherlands
-
Avanir PharmaceuticalsCompletedHealthy Adult Male and Female VolunteersUnited States
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingHealthy Adult Male VolunteersChina
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Sunshine Lake Pharma Co., Ltd.Completed
-
SOFAR S.p.A.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult Male VolunteersChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult Male VolunteersChina
-
Eisai Co., Ltd.Completed
Clinical Trials on SHR3162
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Atridia Pty Ltd.Completed
-
Atridia Pty Ltd.CompletedProstate Cancer | NeoplasmAustralia
-
Atridia Pty Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.UnknownProstate Cancer | Castration-resistant Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownAdvanced Pancreatic CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Tianjin Medical University Second HospitalUnknownSmall Cell Lung Cancer Extensive StageChina
-
Jiangsu HengRui Medicine Co., Ltd.Peking University Cancer Hospital & InstituteCompletedOvarian Cancer | Triple Negative Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Terminated